Shares of Adaptimmune Therapeutics skyrocketed after the company announced an agreement to develop and commercialize allogeneic cell therapies for cancer with Genentech.
Vertex Pharmaceuticals and Arbor Biotechnologies announced a new collaboration to enhance efforts in developing ex vivo engineered cell therapies, using Arbor’s proprietary CRISPR gene-editing technology for select diseases.
Swiss pharma giant Roche announced a partnership with Shape Therapeutics valued at more than $3 billion that will attempt to harness the Seattle-based company’s RNA editing platform to take on neurodegenerative diseases as well as others.
Shoreline Biosciences is developing an off-the-shelf, targeted, allogeneic approach to natural killer (NK) and macrophage cell therapies which the immunotherapy company’s chairman and CEO believes is one-of-a-kind.
An antiviral treatment under development by Atea Pharmaceuticals is showing promise against Covid-19.
The model for healthcare delivery and treatment was upended by the COVID-19 pandemic, as ordinary Americans have learned to take more control of their own care and treatment, harnessing a new class of technology tools that have given individuals unprecedented clout. But patients and healthcare providers still need to partner together for the best outcomes, according to Jim Weiss, founder and CEO of Real Chemistry.
CrowdPharm, an independent full-service agency with one of healthcare’s largest networks of global talent, announced a strategic partnership with True Media to provide integrated, data-driven media strategy that influences customer behavior.
Ashfield Engage (part of UDG Healthcare plc.) announced an investment in Pennsylvania-based PROPENSITY4, formalizing a strategic partnership to deliver optimized omnichannel outreach and customer engagement throughout North America via the integration of data, analytics and insights within its Customer Experience offering. Management says this move solidifies a working partnership between the two companies that has flourished during the past three years.
Global pharmaceutical operations and technology company Biogen partnered with Chinese commercial-stage biopharmaceutical firm InnoCare Pharma to develop a treatment for multiple sclerosis.
ObvioHealth Raises $31 Million, Adds Two Strategic Partners to Bolster Capabilities and Drive Growth Globally NEW YORK, July 1, 2021 /PRNewswire/ — ObvioHealth, a global Virtual Research Organization (VRO), announces it […]